ZVRA Stock Forecast & Price Target

Zevra Therapeutics is well-positioned for success due to its strong market position with MIPLYFFA, the only FDA-approved treatment for NPC, its solid balance sheet and pipeline optionality in rare diseases, and the latest positive incremental development supporting tolerability and dosing confidence for infants with NPC. Recent financing by private Beren, including a single investor providing equity, term loans, and royalty financing for regulatory and revenue milestones, further signals the potential for success in the NPC market and provides additional support for Zevra's own valuation and potential peak sales estimates. However, there are risks to consider, such as payer pushback on pricing, potential competition from AQNEURSA, and delays or challenges in EU approval and reimbursement.

Zevra Therapeutics is facing potential competition from Beren’s adrabetadex for the treatment of NPC in infants, but recent data published on MIPLYFFA has shown promising safety, tolerability, and PK results in patients under the age of 2. However, the company’s valuation is heavily based on the success of MIPLYFFA in the NPC market and may be at risk if other indications for arimoclomol and pipeline products do not come to fruition. Additionally, the company’s weighted average cost of capital is high, leading to a discounted cash flow-based price target of only $29.